Design and rationale of two phase 3 randomised controlled trials (Cough-1 and cough-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

David R. Muccino, Alyn H. Morice, Surinder S. Birring, Peter V. Dicpinigaitis, Ian D. Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A. Smith

Research output: Contribution to journal › Article › peer-review

39 Scopus citations

Fingerprint

Dive into the research topics of 'Design and rationale of two phase 3 randomised controlled trials (Cough-1 and cough-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough'. Together they form a unique fingerprint.

Medicine & Life Sciences